Joshua D Safer MD, FACP's portrait

Joshua D Safer MD, FACP

Associate Professor of Medicine and Molecular Medicine
Boston University School of Medicine
Boston, MA
Dr. Safer is a member of the EndocrineWeb Editorial Board.

About Joshua D Safer MD, FACP

Dr. Joshua Safer is Associate Professor of Medicine and Molecular Medicine, and Associate Chief for Education, Section of Endocrinology, Diabetes, and Nutrition at Boston University School of Medicine in Boston, MA. He is board certified in Endocrinology, Diabetes and Metabolism.

At Boston University School of Medicine, Dr. Safer holds several teaching positions, including:

  • Director, Endocrinology Fellowship Training Program
  • Course Director, Disease and Therapy—Endocrinology Section
  • Course Director, General Medicine and Dental Correlations
  • Regularly lectures on thyroid disease, diabetes insipidus, and transgender medicine.

Dr. Safer received his medical degree from the University of Wisconsin, School of Medicine in Madison, WI. He completed an internship and residency in the Department of Medicine at The Mount Sinai School of Medicine, Beth Israel Medical Center in New York, NY.

Dr. Safer’s academic accomplishments include two fellowships at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston.

  • Clinical and Research Fellow in Endocrinology under the tutelage of Fredric Wondisford, MD; an authority in molecular medicine in endocrinology.  

Dr. Safer is an active member of many prestigious endocrine societies. He serves on the Endocrine Treatment of Transsexual Persons Clinical Practice Guideline Task Force of The Endocrine Society. In addition, Dr. Safer is the President-Elect of the Association of Specialty Profession, Alliance of Academic Internal Medicine (AAIM), and serves on its Council, Program Planning Task Force, and Survey Center Work Group.

Furthermore, he holds leadership roles in other organizations. Association memberships include the World Professional Association for Transgender Health, American Association of Clinical Endocrinologists, and American Thyroid Association.

Currently, Dr. Safer is the Associate Editor of the Journal of Clinical & Translational Endocrinology and Editorial Board Member of Endocrine Practice.

 

Publications

Invited Lectures and Presentations (National/International)

Trangendocrinology. Annual Meeting of the American Association of Clinical Endocrinologists, Las Vegas, NV. May, 2014.

Transgender Therapy – Hormone Action and Nuance. National Transgender Health Summit, Oakland, CA. May, 2013.

Transgender Therapy – What Every Provider Needs to Know. Empire Conference: Transgender Health and Wellness, Albany, NY. April, 2013.

Transgender Therapy – What Every Endocrinologist Needs to Know. University of Maryland School of Medicine, Baltimore, MD. April, 2013.

Transgender Therapy – What Every Endocrinologist Should Know. New York University School of Medicine, New York, NY. November, 2012.

Transgender Therapy – The Endocrine Society Guidelines. World Professional Association for Transgender Health Pre-Conference, Atlanta, GA. September, 2011.

Transgender Treatment: What Every Endocrinologist Needs to Know. Brown University School of Medicine, Providence, RI. May, 2010.

New Directions in Thyroid Hormone Action: Skin and Hair. Emory University School of Medicine, Atlanta, GA. November, 2009.

Primary Care Update in the Treatment of Thyroid Disorders. Emory University School of Medicine, Atlanta, GA. November, 2009.

Topical iopanoic acid stimulates epidermal proliferation through inhibition of the type 3 thyroid hormone deiodinase. American Thyroid Association annual meeting, Chicago, IL. October, 2008.

Treating skin disease by manipulating thyroid hormone action. Grand Rounds, Meier Hospital, Kfar Saba, Israel. February, 2007.

Transgender Therapy: The Role of the Endocrinologist. Endocrinology Grand Rounds, Tufts-New England Medical Center, Boston, Massachusetts. May, 2005.

New Directions in Thyroid Hormone Action: Skin and Hair. Endocrinology Grand Rounds, University of Minnesota, Minneapolis, Minnesota. February, 2005.

Thyroid Hormone Action on Skin and Hair: What We Thought We Knew. Dermatology Grand Rounds, University of Minnesota, Minneapolis, Minnesota. February, 2005.

New Directions in Thyroid Hormone Action: Skin and Hair. Grand Rounds, Meier Hospital, Kfar Saba, Israel. March, 2004.

New Directions in Thyroid Hormone Action: Skin and Hair. Endocrinology Grand Rounds, Brigham and Women's Hospital, Boston, Massachusetts. January, 2004.

New Directions in Thyroid Hormone Action: Skin and Hair. Endocrinology Grand Rounds, Dartmouth Medical Center, Hanover, New Hampshire. November, 2003.

Central Resistance to Thyroid Hormone – From Bedside to Bench. Endocrinology Grand Rounds, Boston University Medical Center, Boston, Massachusetts. November, 1999.

The Many Faces of Hypothyroidism. Medical Grand Rounds, Bedford Veterans Administration Hospital, Bedford, Massachusetts. October, 1999.

Original, Peer-Reviewed Articles

1. Safer JD, Langlois MF, Cohen R, Monden T, John-Hope D, Madura J, Hollenberg AN, Wondisford FE. Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone. Molecular Endocrinology 1997;11(1):16-26. PMID 8994184/

2. Langlois MF, Zanger K, Monden T, Safer JD, Hollenberg AN, Wondisford FE. A unique role of the beta-2 thyroid hormone receptor isoform in negative regulation by thyroid hormone - mapping of a novel amino-terminal domain important for ligand-independent activation. Journal of Biological Chemistry 1997;272(40):24927-24933. PMID 9312095/

3. Safer JD, Cohen RN, Hollenberg AN, Wondisford, FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. Journal of Biological Chemistry 1998;273(46):30175-30182. PMID 9804773

4. Safer JD, O'Connor MG, Colan SD, Srinivasan S, Tollin SR, Wondisford FE. The TR-beta gene mutation R383H is associated with isolated central resistance to thyroid hormone. Journal of Clinical Endocrinology and Metabolism 1999;84(9):3099-3109. PMID 10487671

5. Safer JD, Fraser LM, Ray S, Holick MF. Topically applied triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. Thyroid 2001;11(8):717-724. PMID 11525263

6. Tangpricha V, Chen BJ, Swan NC, Sweeney AT, de las Morenas A, Safer JD. Twenty-one gauge needles provide more cellular samples than twenty-five gauge needles in fine needle aspiration biopsy of the thyroid. Thyroid 2001;11(10):973-976. PMID 11716046

7. Safer JD, Crawford TM, Fraser LM, Hoa M, Ray S, Chen TC, Persons K, Holick MF. Thyroid hormone action on skin: diverging effects of topical versus intraperitoneal administration. Thyroid 2003;13(2):159-165. PMID 12699590

8. Santini F, Ceccarini G, Montanelli L, Rosellini V, Mammoli C, Macchia P, Gatti G, Pucci E, Marsili A, Chopra IJ, Chiovato L, Vitto P, Safer JD, Braverman LE, Martino E, Pinchera A. Role for inner ring deiodination preventing transcutaneous passage of thyroxine. Journal of Clinical Endocrinology and Metabolism 2003;88(6):2825-2830. PMID 12788895

9. Safer JD, Crawford TM, Holick MF. A role for thyroid hormone in wound healing through keratin gene expression. Endocrinology 2004;145(5):2357-2361. PMID 14736740

10. Safer JD, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. Endocrinology 2005;146(10):4425-4430. PMID 15976059

11. Saha AK, Persons K, Safer JD, Luo Z, Holick MF, Ruderman NB. AMPK regulation of the growth of cultured human keratinocytes. Biochemical and Biophysical Research Communications 2006;349(2):519-24. PMID 16949049

12. Safer JD, Ray S, Holick MF. A topical PTH/PTHrP receptor antagonist stimulates hair growth in mice. Endocrinology 2007;148(3):1167-1170. PMID 17170098

13. Safer JD, Persons K, Holick MF. A thyroid hormone deiodinase inhibitor can decrease cutaneous cell proliferation in vitro. Thyroid 2009;19(2):181-185. PMID 19191748

14. Ariza MA, Loken WM, Pearce EN, Safer JD. Male sex, African-American race/ethnicity, and T3 levels at diagnosis are predictors of weight gain following medication and radioactive iodine treatment for hyperthyroidism. Endocrine Practice 2010;16(4):609-616. PMID 20350916

15. Abraham TM, de las Morenas A, Lee SL, Safer JD. In thyroid fine needle aspiration, use of bedside-prepared slides significantly increased diagnostic adequacy and specimen cellularity relative to solution-based samples. Thyroid 2011;21(3):237-242. PMID 21323589

16. Huang MP, Rodgers KA, O'Mara R, Mehta M, Abuzahra HS, Tannenbaum AD, Persons K, Holick MF, Safer JD. The thyroid hormone degrading Dio3 is the primary deiodinase active in murine epidermis. Thyroid 2011;21(11):1263-1268. PMID 21936673

17. Toraldo G, Bhasin S, Bakhit M, Guo W, Serra C, S, Safer JD, Bhawan J, Jasuja R. Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking beta-catenin nuclear translocation and cross-talk with TGF-beta signaling in keratinocytes. Wound Rep Reg 2012;20:61-73. PMID 22276587

18. Safer JD, Pearce EN. A simple curriculum content change increased medical student comfort with transgender medicine. Endocrine Practice 2013;19(4):633-637. PMID 23425656

19. Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: A diagnostic dilemma. Thyroid 2001;11(3):281-291. PMID 11327621

20. Safer JD, Hennessey JV, Braverman LE. Substituting brand name levothyroxine preparations with generics would increase treatment cost. Annals of Internal Medicine 2005;on-line available at http://www.annals.org/cgi/eletters/142/11/891#1882.

21. Pietras SM, Safer JD. A spurious elevation of both total thyroid hormone and thyroid hormone uptake measurements in the setting of autoantibodies may result in diagnostic confusion: A case report and review of the related literature. Endocrine Practice 2008;14(6):738-742. PMID 18996795

22. Safer JD, Tangpricha V. Out of the Shadows: It is time to mainstream treatment for transgender patients. Endocrine Practice 2008;14(2):248-50. PMID 18308667

23. Feldman J, Safer JD, Hormone therapy in adults: Suggested revisions to the sixth version of the Standards of Care. International Journal of Transgenderism 2009;11(3):146-182.

24. Bhasin S, Safer JD, Tangpricha V. The Hormone Foundation's patient guide to the endocrine treatment of transsexual persons. Journal of Clinical Endocrinology and Metabolism 2009;94(9).

25. Safer JD. Thyroid hormone action on skin. Dermato-Endocrinology 2011;3(3):1-5. PMID 22110782

26. Kannan S, Safer JD. Finding the right balance between resistance & sensitivity -- A case report and brief review of the cardiac manifestations of the syndrome of resistance to thyroid hormone and the implications for treatment. Endocrine Practice 2012; 18(2):252-255. PMID 22068246

27. Safer JD. Thyroid hormone action on skin. Curr Opin Endocrinol Diabetes Obes 2012;19(5):388-293. PMID 22914563

28. Safer JD. 2013 Thyroid hormone and wound healing. Journal of Thyroid Research doi:10.1155/2013/124538. PMID 23577275

29. Safer JD. Transgender medical research, provider education, and patient access are overdue. Endocrine Practice 2013;19(4):575-6. PMID 23337168

30. Gardner IH, Safer JD. Progress on the road to better medical care for transgender patients. Curr Opin Endocrinol Diabetes Obes 2013;20(6):553-558. PMID 24468757

Textbook Chapters

Safer JD, Wondisford FE. 1997 TSH, Normal Physiology, Contemporary Endocrinology: Diseases of the Pituitary, Wierman ME, ed., Humana Press Inc., Totowa, NJ, 283-293.

Safer JD. 2003 Resistance to Thyroid Hormone, Contemporary Endocrinology: Diseases of the Thyroid, 2nd Edition, Braverman LE, ed., Humana Press Inc., Totowa, NJ, 199-216.

Safer JD. 2005 The skin in thyrotoxicosis, Werner and Ingbar's The Thyroid, 9th Edition, Braverman LE and Utiger RD, eds., Lippincott Williams and Williams, Philadelphia, PA, 553-558.

Safer JD. 2005 The skin and connective tissue in hypothyroidism, Werner and Ingbar's The Thyroid, 9th Edition, Braverman LE and Utiger RD, eds., Lippincott Williams and Williams, Philadelphia, PA, 769-773.

Safer JD, Holick MF. 2008 Potential therapeutic uses of thyroid hormone, Thyroid Disorders with Cutaneous Manifestations, Heymann WR, ed., Springer-Verlag, London, UK 181-186.

Leung AM, Safer JD. 2012 Thyrotoxicosis of extra thyroid origin, Werner and Ingbar's The Thyroid, 10th Edition, Braverman LE and Cooper D, eds., Lippincott Williams and Williams, Philadelphia, PA, 429-433.

Case Reports

Koutkia P, Safer JD. Adrenal metastasis secondary to papillary thyroid carcinoma. Thyroid. 2001;11(11):1077-1079. PMID 11762719

Choong K, Safer JD. Graves disease and gynecomastia in two roomates. Endocrine Practice. 2011;17(4):647-650. PMID 21613048

Published Abstracts

Safer JD, Crawford TM, Holick MF Topical iopanoic acid inhibits epidermal proliferation in mice. Thyroid. 2004;14(9):703.

Safer JD, Persons K, Holick MF Iopanoic acid inhibits fibroblast proliferation by interfering with T4 to T3 conversion. Thyroid. 2006;16(9):882.

Safer JD, Persons K, Holick MF While T3 can reverse the inhibition of keratinocyte proliferation caused by iopanoic acid, T4 cannot. Thyroid. 2007;17(s1):S-129-S-130.

Safer JD, Persons K, Holick MF Topical iopanoic acid stimulates epidermal proliferation through inhibition of the type 3 thyroid hormone deiodinase. Thyroid. 2008;18(s1):S-37-S-38.

Choong K, Safer JD Topical thyroid hormone accelerates wound healing in diabetic mice. Endocrine Review. 2011;32:P3-595.

Safer JD A simple curriculum change increased medical student comfort with transgender medicine. Endocrine Review. 2012; 33(3):OR39-4.

Articles Written by Joshua D Safer MD, FACP

Transgender Hormone Therapy Is Safe When Monitored For Certain Risks
One of the most often cited reasons by medical providers for hesitation in providing hormone therapy to transgender individuals is the fear of harm. The review demonstrates that hormone therapy is relatively safe, at least as far as the modest literature out there can determine.
Hormone Therapy Is Safe in Transgender Adults When Carefully Monitored
04/06/2015 - This review of current studies suggests that transgender hormone therapy is relatively safe for most people. The harms that do exist are relatively rare and can often be avoided with monitoring.
Transgender Medicine: Clinical Care of Adolescents
EndocrineWeb's interview about transgender medicine with Joshua D. Safer, MD, FACP continues and focuses on clinical care of adolescents. Dr. Safer serves on The Endocrine Society’s Endocrine Treatment of Transsexual Persons Clinical Practice Guideline Task Force.
Transgender Medicine
EndocrineWeb spoke with Joshua Safer, MD, who serves on The Endocrine Society’s Endocrine Treatment of Transsexual Persons Clinical Practice Guideline Task Force. Here, Dr. Safer provides clinicians an overview of gender identity disorder and transgender medicine.

Financial Disclosures for Joshua D Safer MD, FACP

EndocrineWeb, a Vertical Health, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.

To help achieve this goal, EndocrineWeb requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.

The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.

Author's Statement

I, the undersigned, declare that neither I nor members of my immediate family have a financial interests or affiliation with commercial companies whose products and / or services may be mentioned in the materials I have authored, edited or reviewed for presentation on Vertical Health, LLC’s websites.
There are no disclosures for this author
SHOW MAIN MENU
SHOW SUB MENU